Viral Envelope Protein-Host Cell Surface Receptor Interaction

Viral envelope proteins and host cell surface receptors represent the primary interface for viral infection. Enveloped viruses utilize surface glycoproteins to recognize and bind specific host receptors, initiating the process of viral entry via membrane fusion or endocytosis (Marsh & Helenius, 2006, Cell). For example, the SARS-CoV-2 Spike protein binds to the human ACE2 receptor, while HIV-1 gp120 interacts with CD4 and co-receptors like CCR5 or CXCR4 (Lan et al., 2020, Nature; Wilen et al., 2012, CSH Perspect Med). These interactions are critical therapeutic targets, as blocking them can prevent the virus from entering host cells and establishing infection. Drugs targeting this interface include monoclonal antibodies, fusion inhibitors, and small molecule receptor antagonists (Tilton & Doms, 2010, Antiviral Res). However, the high mutation rate of viral envelope proteins often leads to the emergence of resistant strains, posing a significant challenge for long-term efficacy (Tang et al., 2021, BMJ). Additionally, targeting host receptors may interfere with their endogenous physiological functions (Meanwell & Kadow, 2007, Curr Opin Drug Discov Devel).

Other names

Viral entry interfaceVirus-host cell attachment complexViral fusion machineryViral entry receptorsViral attachment proteins

Inhibition of viral entry by blocking the binding of viral envelope glycoproteins to host cell surface receptors or by preventing subsequent membrane fusion events.